The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).
 
Chethan Ramamurthy
Honoraria - Gilead Sciences
Consulting or Advisory Role - Exelixis; Seagen
Research Funding - Dispersol (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Seagen (Inst)
 
Alejandro Recio-Boiles
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Julia Tonelli
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Myovant Sciences
 
Mitch Sierecki
Employment - Bayer; Gilead Sciences
Stock and Other Ownership Interests - Bayer; Gilead Sciences
 
Philippe Barthélémy
Honoraria - Astellas Amgen BioPharama; Bristol-Myers Squibb; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Eisai; Ipsen; Janssen; Merck; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer